Glyburide and metformin Side Effects
Please note - some side effects for Glyburide and metformin may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the professional |
|
For the professional
Glyburide and Metformin
Glyburide and Metformin Hydrochloride
In double-blind clinical trials involving Glyburide and Metformin hydrochloride as initial therapy or as second-line therapy, a total of 642 patients received Glyburide and Metformin hydrochloride, 312 received metformin therapy, 324 received glyburide therapy, and 161 received placebo. The percent of patients reporting events and types of adverse events reported in clinical trials of Glyburide and Metformin hydrochloride (all strengths) as initial therapy and second-line therapy are listed in Table 6.
| Adverse Event | Number (%) of Patients | |||
|---|---|---|---|---|
| Placebo N=161 |
Glyburide N=324 |
Metformin N=312 |
Glyburide and Metformin Hydrochloride N=642 |
|
| Upper respiratory infection |
22 (13.7) |
57 (17.6) |
51 (16.3) |
111 (17.3) |
| Diarrhea |
9 (5.6) |
20 (6.2) |
64 (20.5) |
109 (17) |
| Headache |
17 (10.6) |
37 (11.4) |
29 (9.3) |
57 (8.9) |
| Nausea/vomiting |
10 (6.2) |
17 (5.2) |
38 (12.2) |
49 (7.6) |
| Abdominal pain |
6 (3.7) |
10 (3.1) |
25 (8) |
44 (6.9) |
| Dizziness |
7 (4.3) |
18 (5.6) |
12 (3.8) |
35 (5.5) |
In a controlled clinical trial of rosiglitazone versus placebo in patients treated with Glyburide and Metformin hydrochloride (n=365), 181 patients received Glyburide and Metformin hydrochloride with rosiglitazone and 184 received Glyburide and Metformin hydrochloride with placebo.
Edema was reported in 7.7% (14/181) of patients treated with rosiglitazone compared to 2.2% (4/184) of patients treated with placebo. A mean weight gain of 3 kg was observed in rosiglitazone-treated patients.
Disulfiram-like reactions have very rarely been reported in patients treated with glyburide tablets.
Hypoglycemia
In controlled clinical trials of Glyburide and Metformin hydrochloride there were no hypoglycemic episodes requiring medical intervention and/or pharmacologic therapy; all events were managed by the patients. The incidence of reported symptoms of hypoglycemia (such as dizziness, shakiness, sweating, and hunger), in the initial therapy trial of Glyburide and Metformin hydrochloride are summarized in Table 7. The frequency of hypoglycemic symptoms in patients treated with Glyburide and Metformin hydrochloride 1.25 mg/250 mg was highest in patients with a baseline HbA1c <7%, lower in those with a baseline HbA1c of between 7 and 8%, and was comparable to placebo and metformin in those with a baseline HbA1c >8%. For patients with a baseline HbA1c between 8% and 11% treated with Glyburide and Metformin hydrochloride 2.5 mg/500 mg as initial therapy, the frequency of hypoglycemic symptoms was 30 to 35%. As second-line therapy in patients inadequately controlled on sulfonylurea alone, approximately 6.8% of all patients treated with Glyburide and Metformin hydrochloride experienced hypoglycemic symptoms. When rosiglitazone was added to Glyburide and Metformin hydrochloride therapy, 22% of patients reported one or more fingerstick glucose measurements ≤50 mg/dL compared to 3.3% of placebo-treated patients. All hypoglycemic events were managed by the patients and only one patient discontinued for hypoglycemia.
Gastrointestinal Reactions
The incidence of GI side effects (diarrhea, nausea/vomiting, and abdominal pain) in the initial therapy trial are summarized in Table 7. Across all Glyburide and Metformin hydrochloride trials, GI symptoms were the most common adverse events with Glyburide and Metformin hydrochloride and were more frequent at higher dose levels. In controlled trials, <2% of patients discontinued Glyburide and Metformin hydrochloride therapy due to GI adverse events.
| Variable | Placebo N=161 |
Glyburide Tablets N=160 |
Metformin Tablets N=159 |
Glyburide and Metformin Hydrochloride 1.25 mg/250 mg Tablets N=158 |
Glyburide and Metformin Hydrochloride 2.5 mg/500 mg Tablets N=162 |
|---|---|---|---|---|---|
| Mean Final Dose |
0 mg |
5.3 mg |
1317 mg |
2.78 mg/557 mg |
4.1 mg/824 mg |
| Number (%) of patients with symptoms of hypoglycemia |
5 (3.1) |
34 (21.3) |
5 (3.1) |
18 (11.4) |
61 (37.7) |
| Number (%) of patients with gastrointestinal adverse events |
39 (24.2) |
38 (23.8) |
69 (43.3) |
50 (31.6) |
62 (38.3) |
Top
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
